
Hidradenitis Suppurativa Factors Affecting Patient Quality of Life
Researchers say disease severity, site, and comorbidities may lower a patient’s quality of life as they navigate hidradenitis suppurativa.
Patients with
Researchers conducted an
Through an observational, questionnaire-formatted study, researchers gathered information from 30 patients (ages 18 to 63) with a clinical HS diagnosis.
Study participants provided relevant data, including demographic (age, body mass index, gender, height, weight) and disease (duration, location, number and morphology of lesions, and
Following the study’s conclusion, researchers noted a statistically significant relationship between a patient’s Hurley staging system and DLQI scores—noting that as a patient’s disease increased in severity, their overall quality of life decreased accordingly.
Participants with HS located in their abdomen, back, gluteal, neck, and thigh regions also demonstrated a lower overall quality of life association, despite the axilla and groin regions being the most prevalently affected.
Study participants who had scars or surgery related to their HS also demonstrated a lower DLQI with a significant association noted by researchers. Researchers attribute these findings to the hinderance these factors may have on a patient’s daily activities.
On average, the mean DLQI score among study participants was 9.47 ± 5.69, or a significant association between quality of life and disease factors, though researchers said this is a much lower mean than those determined by studies of a similar nature. This is believed to have been due to the number of participants in the study falling under Hurley stage 1.
However, contrary to
The study also found that HS had a higher DQLI than other dermatological conditions, including
“Hidradenitis suppurativa is not a life-threatening disease, but it has a considerable impact on the deteriorating quality of life,” the study said. “Our study will help in planning healthcare policies according to the disease burden.”
References
1. Menon A, Gupta P, Suri RK, Thakare V, Dubey lily, Patil S.
2. Krajewski PK, Matusiak Ł, von Stebut E, Schultheis M, Kirschner U, Nikolakis G, Szepietowski JC:
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















